Oruka Therapeutics
ORKA
71 hedge funds and large institutions have $326M invested in Oruka Therapeutics in 2025 Q1 according to their latest regulatory filings, with 16 funds opening new positions, 28 increasing their positions, 12 reducing their positions, and 10 closing their positions.
133% more repeat investments, than reductions
Existing positions increased: 28 | Existing positions reduced: 12
60% more first-time investments, than exits
New positions opened: 16 | Existing positions closed: 10
33% more funds holding in top 10
Funds holding in top 10: 3 → 4 (+1)
8% more funds holding
Funds holding: 66 → 71 (+5)
3.81% less ownership
Funds ownership: 88.68% → 84.87% (-3.8%)
46% less capital invested
Capital invested by funds: $607M → $326M (-$281M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VA
VR Adviser
New York
|
+$10.8M |
| 2 |
DTC
Deep Track Capital
Greenwich,
Connecticut
|
+$8.66M |
| 3 |
Blackstone Inc
New York
|
+$6.78M |
| 4 |
PCH
Polar Capital Holdings
London,
United Kingdom
|
+$6.24M |
| 5 |
B
Braidwell
Stamford,
Connecticut
|
+$5.3M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Janus Henderson Group
London,
United Kingdom
|
-$16.4M |
| 2 |
PA
Perceptive Advisors
New York
|
-$16.4M |
| 3 |
PBA
Paradigm Biocapital Advisors
New York
|
-$15.9M |
| 4 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$11.4M |
| 5 |
DCM
Driehaus Capital Management
Chicago,
Illinois
|
-$5.99M |
ORKA Hedge Fund Activity: Q1 2025 in Review
71 of the 7,457 institutional investors tracked by Wall St. Rank reported a position in Oruka Therapeutics (ORKA) for Q1 2025, worth a combined $326M — down 46% from $607M a quarter earlier.
Buyers outnumbered sellers: 16 funds opened new ORKA positions and 10 closed out — a net gain of 6 holders — while 28 added to existing stakes and 12 trimmed.
The largest buyer was VR Adviser, adding an estimated $10.8M. The largest seller was Janus Henderson Group, exiting entirely with an estimated $16.4M sold.
- 71 institutional investors held Oruka Therapeutics (ORKA) as of Q1 2025, up from 66 in Q4 2024.
- Funds reported $326M of Oruka Therapeutics stock for Q1 2025, down 46% quarter-over-quarter.
- 16 funds opened new Oruka Therapeutics positions in Q1 2025 and 10 closed out, a net change of +6 holders.
- The largest Oruka Therapeutics buyer in Q1 2025 was VR Adviser, an estimated $10.8M added.
- The largest Oruka Therapeutics seller in Q1 2025 was Janus Henderson Group, an estimated $16.4M sold.
Based on aggregated 13F filings for Q1 2025.